Why is it now considered a later-line osteoporosis drug?

More effective agents such as bisphosphonates are available, and regulators flagged a possible small increase in cancer risk with long-term use.

Most commonly as a once-daily nasal spray for osteoporosis, or by subcutaneous or intramuscular injection for hypercalcemia and Paget's disease.

Is the cancer risk proven?

No. Reviews describe the association as weak and of uncertain causality, but regulators acted cautiously and limited long-term intranasal use.

What are the common side effects?

Nasal spray can cause a runny nose, nasal irritation, and nosebleeds; injections can cause nausea, flushing, and injection-site reactions.

FDA-approved medicineaka Salmon calcitonin, Salcatonin, Miacalcin, Fortical

Calcitonin (salmon) — Complete Research Guide (2026)

Last updated 2026-07-31

TL;DR

A 32-amino-acid peptide hormone, FDA-approved for postmenopausal osteoporosis, Paget disease and hypercalcemia; now a later-line option.

What is Calcitonin (salmon)?

Salmon calcitonin (brand names Miacalcin and Fortical) is a 32-amino-acid peptide hormone that is FDA-approved for postmenopausal osteoporosis, Paget's disease of bone, and hypercalcemia, and is given as a nasal spray or by injection.

It is now generally considered a later-line option for osteoporosis, because more effective agents exist and because regulators flagged a possible small increase in cancer risk with long-term use.

The evidence base includes multi-year randomized controlled trials for osteoporosis (for example the PROOF study) as well as regulatory meta-analyses examining the cancer signal.

How does Calcitonin (salmon) work?

Calcitonin binds calcitonin receptors on osteoclasts, inhibiting osteoclast-mediated bone resorption and reducing the release of calcium from bone into the bloodstream.

What does the research say about Calcitonin (salmon)?

In the 5-year PROOF randomized controlled trial, nasal salmon calcitonin 200 IU/day reduced the risk of new vertebral fractures in postmenopausal women with established osteoporosis versus placebo. ^[1]
A 2-year randomized dose-response trial found intranasal salcatonin increased or preserved bone mass in elderly women with moderate osteoporosis. ^[2]
Systematic review of the safety data concluded the association between salmon calcitonin and cancer is weak and of uncertain causality. ^[4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group — Chesnut CH 3rd et al., American Journal of Medicine 2000. (5-year phase 3 randomized placebo-controlled trial)
[2] Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study — Overgaard K et al., BMJ 1992. (2-year randomized double-blind placebo-controlled dose-response trial)
[3] A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial — Binkley N et al., Journal of Bone and Mineral Research 2012. (Phase 3 randomized controlled trial (investigational oral formulation))
[4] Does salmon calcitonin cause cancer? A review and meta-analysis — Wells G et al., Osteoporosis International 2016. (Review and meta-analysis)
[5] Salmon calcitonin use and associated cancer risk — Overman RA et al., Annals of Pharmacotherapy 2013. (Systematic review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In the pivotal osteoporosis trial the studied regimen was 200 IU intranasally once daily together with calcium and vitamin D supplementation, while hypercalcemia and Paget's disease have historically used injectable dosing.

These figures describe studied and labeled use for context only and are not a dosing recommendation; treatment must be directed by a licensed clinician.

Side effects & safety profile

Regulatory reviews by the FDA and EMA flagged a small but statistically observed increase in overall cancer rates among long-term calcitonin users, which led to restrictions particularly on long-term intranasal use; the causal relationship remains debated.

Nasal spray commonly causes rhinitis, nasal irritation, and nosebleeds, while injectable forms cause nausea, flushing, and injection-site reactions.

Because more effective antiresorptive agents are available and because of the cancer signal, calcitonin is now typically reserved as a later-line osteoporosis therapy.

Stacking & combinations

Calcitonin is used as a single agent, typically alongside calcium and vitamin D supplementation, rather than stacked with other peptides.

Finding Calcitonin (salmon) vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

FDA-approved uses include postmenopausal osteoporosis, Paget's disease of bone, and hypercalcemia.

References

[1] A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group — Chesnut CH 3rd et al., American Journal of Medicine 2000. PMID: 10996576. View sourceStudy: 5-year phase 3 randomized placebo-controlled trialNasal salmon calcitonin 200 IU/day reduced new vertebral fracture risk versus placebo in postmenopausal osteoporosis.
[2] Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study — Overgaard K et al., BMJ 1992. PMID: 1393035. View sourceStudy: 2-year randomized double-blind placebo-controlled dose-response trialIntranasal salcatonin increased bone mass in elderly women with moderate osteoporosis in a dose-related manner.
[3] A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial — Binkley N et al., Journal of Bone and Mineral Research 2012. PMID: 22437792. View sourceStudy: Phase 3 randomized controlled trial (investigational oral formulation)An oral recombinant calcitonin tablet raised bone mineral density and lowered bone-turnover markers versus placebo.
[4] Does salmon calcitonin cause cancer? A review and meta-analysis — Wells G et al., Osteoporosis International 2016. PMID: 26438308. View sourceStudy: Review and meta-analysisConcluded a causal link between calcitonin and malignancy is unlikely, with little biological plausibility.
[5] Salmon calcitonin use and associated cancer risk — Overman RA et al., Annals of Pharmacotherapy 2013. PMID: 24259626. View sourceStudy: Systematic reviewFound the evidence for a calcitonin-cancer association to be limited and inconsistent, warranting caution rather than proof of harm.

Related peptides

TeriparatideHormones & Metabolic AbaloparatideHormones & Metabolic

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.